Abstract: An electronic device called HELU (Hawaiian for tally) which can monitor medical body metrics and quantify/measure sexual performance as a number of strokes and pressure achieved as data for analyzing erectile dysfunction. The device can measure body metrics during sexual activity and at rest. The measurement data can be monitored, recorded and displayed, and analyzed/compared for a predetermined set of body metrics such as heart rate, pulse, blood pressure, calories burned, the tally and of strokes, and the pressure achieved during activity or at rest. The HELU communicates wirelessly to personal communication devices—smart phones, tablets, laptops, and personal computers. Analysis is supported by graphs displaying the data of body metrics and erectile dysfunction data. The data can be evaluated and considered for medical analysis, for physical status, for progress toward goals, and for games, competitive contests, and for personal amusement.

Abstract: The present invention provides automated methods for expanding TILs and producing therapeutic populations of TILs, including novel tissue culture devices and automated methods for expanding TIL populations in a closed system that lead to improved efficacy, improved phenotype, and increased metabolic health of the TILs in a shorter time period, while allowing for reduced microbial contamination as well as decreased costs.

Abstract: Chemically induced dimerizers (AbCIDs) have emerged as one of the most powerful tools to artificially regulate signaling pathways in cells; however, no facile method to identify or design these systems currently exists. The present invention provides a methodology to rapidly generate antibody-based chemically induced dimerizers (AbCIDs) from known small-molecule-protein complexes by selecting for synthetic antibodies that recognize the chemical epitope created by the bound small molecule. Success of this strategy is demonstrated by generating ten chemically-inducible antibodies against the BCL-xL/ABT-737 complex. Three of the antibodies are highly selective for the BCL-xL/ABT-737 complex over BCL-xL alone. Two exemplary important cellular applications of AbCIDs are demonstrated by applying them intracellularly to induce CRISPRa-mediated gene expression and extracellularly to regulate CAR T-cell activation with the small molecule, ABT-737.

Abstract: The present disclosure relates to targeted degradation platform technology. For example, the present disclosure relates to bispecific binding agents for degrading endogenous proteins, whether membrane-associated or soluble, using the lysosome pathway. The disclosure also provides methods useful for producing such agents, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various disorders.

Abstract: An interfacing structure for a mask system includes a cushion component adapted to contact the patient's face in use and a cushion-to-frame component provided to the cushion component. The cushion-to-frame component is structured to secure the cushion component to a mask frame of the mask system. The cushion-to-frame component includes a cushion side adapted to interface with the cushion component and a frame side adapted to interface with the mask frame. The cushion side includes a platform to engage and support the cushion component. The platform provides an engagement surface to engage the cushion component and inner and outer flanges provided to opposing ends of the platform to guide, support and/or retain the cushion component on the platform.

Abstract: A patient interface including a positioning and stabilizing structure that is configured to maintain a first seal-forming structure and a second seal-forming structure in a therapeutically effective position. The positioning and stabilizing structure comprises a frame coupled to the plenum chamber. The frame includes a central portion coupled to the plenum chamber outside of the cavity. The frame also includes a pair of arms that extend away from the central portion in a posterior direction past the second seal-forming structure. The pair of arms are more flexible than the central portion. The positioning and stabilizing structure also includes headgear straps coupled to the frame, which configured to provide a tensile force to the first seal-forming structure and to the second seal-forming structure into the patient's face via the frame.

Abstract: The present disclosure relates to targeted degradation platform technology. For example, the present disclosure relates to bispecific binding agents for degrading endogenous proteins, whether membrane-associated or soluble, using the lysosome pathway. The disclosure also provides methods useful for producing such agents, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various disorders.

Abstract: The present disclosure relates to, among other things, methods for degrading targeted surface proteins using the ubiquitin pathway by using a bispecific binding agent or an immunoconjugate that binds the targeted surface protein and a membrane-associated ubiquitin E3 ligase. The present disclosure also relates to methods for degrading targeted surface proteins using the ubiquitin pathway using an engineered transmembrane protein that binds the targeted surface protein and exhibits ubiquitin E3 ligase activity. The disclosure also provides compositions and methods useful for producing such bispecific binding agents and engineered transmembrane proteins, immunoconjugates, nucleic acids encoding same, host cells genetically modified with the nucleic acids, as well as methods for modulating an activity of a cell and/or for the treatment of various diseases such as cancers.

Abstract: This disclosure describes techniques for providing multiple namespace support to application(s) in containers under Kubernetes without breaking containment boundaries or escalating privileges of the application(s). A namespace service executing on a physical server may communicate with contained processes executing on the physical server by utilizing a Unix Domain Socket (UDS) endpoint in the filesystem of each of the containers. the namespace service may execute on the physical server with escalated privileges, allowing the namespace service to create a socket in a namespace and provide access and rights to utilize the socket to process(es) in a separate namespace.

Abstract: Techniques and mechanisms to reduce double encryption of packets that are transmitted using encrypted tunnels. The techniques described herein include determining that portions of the packets are already encrypted, identifying portions of the packets that are unencrypted, and selectively encrypting the portions of the packets that are unencrypted prior to transmission through the encrypted tunnel. In this way, potentially private or sensitive data in the packets that is unencrypted, such as information in the packet headers, will be encrypted using the encryption protocol of the encrypted tunnel, but the data of the packets that is already encrypted, such as the payload, may avoid unnecessary double encryption. By reducing (or eliminating) the amount of data in data packets that is double encrypted, the amount of time taken by computing devices, and computing resources consumed, to encrypted traffic for encrypted tunnels may be reduced.

Abstract: This disclosure describes techniques for providing a distributed scalable architecture for Network Address Translation (NAT) systems with high availability and mitigations for flow breakage during failover events. The NAT servers may include functionality to serve as fast-path servers and/or slow-path servers. A fast-path server may include a NAT worker that includes a cache of NAT mappings to perform stateful network address translation and to forward packets with minimal latency. A slow-path server may include a mapping server that creates new NAT mappings, depreciates old ones, and answers NAT worker state requests. The NAT system may use virtual mapping servers (VMSs) running on primary physical servers with state duplicated VMSs on different physical failover servers.

Abstract: Protein biosensors and methods of using these sensors to detect anti-SARS-CoV-2 patient antibodies (Abs) in a solution-based, rapid, and quantitative COVID-19 serological assay are provided. In certain aspects, the sensors each comprise a first fusion protein that comprises a first SARS-CoV-2 viral protein and a first peptide fragment of a split reporter protein, and a second fusion protein that comprises a second fusion protein that comprises a second SARS-CoV-2 viral protein domain and a second peptide fragment of the split reporter protein. Only if the test sample comprise SARS-CoV- antibodies, the first and second peptide fragments associate to produce an enzymatically active reporter protein.

Abstract: Techniques and mechanisms to reduce double encryption of packets that are transmitted using encrypted tunnels. The techniques described herein include determining that portions of the packets are already encrypted, identifying portions of the packets that are unencrypted, and selectively encrypting the portions of the packets that are unencrypted prior to transmission through the encrypted tunnel. In this way, potentially private or sensitive data in the packets that is unencrypted, such as information in the packet headers, will be encrypted using the encryption protocol of the encrypted tunnel, but the data of the packets that is already encrypted, such as the payload, may avoid unnecessary double encryption. By reducing (or eliminating) the amount of data in data packets that is double encrypted, the amount of time taken by computing devices, and computing resources consumed, to encrypted traffic for encrypted tunnels may be reduced.

Abstract: Techniques are described for configuring and using analytics for requested software components deployed within cloud-based and other distributed computing environments. An orchestration system may determine particular analytics for a requested component implemented within a computing environment, based on the deployed workloads and/or computing resources on which the requested component was deployed. In conjunction with orchestration of the requested component, the orchestration system may determine the associated performance metrics, including particular telemetry metrics and/or composite metrics, based on the orchestration of the requested component. The orchestration system also may manage the presentation of the performance analytics for the requested component, including customized dashboards with component-specific metrics and/or alerts to target devices associated with the requested component.

Abstract: Techniques for load balancing communication sessions in a networked computing environment are described herein. The techniques may include establishing a first communication session between a client device and a first computing resource of a networked computing environment. Additionally, the techniques may include storing, in a data store, data indicating that the first communication session is associated with the first computing resource. The techniques may further include receiving, at a second computing resource of the networked computing environment, traffic associated with a second communication session that was sent by the client device, and based at least in part on accessing the data stored in the data store, establishing a traffic redirect such that the traffic and additional traffic associated with the second communication session is sent from the second computing resource to the first computing resource.

Abstract: The disclosure is related to antibodies and antibody fragments that specifically bind the CUB domain-containing protein 1 (CDCP1) and their methods and uses in treating and detecting cancers.

Abstract: This disclosure describes recombinant angiotensin-converting enzyme II (ACE2) polypeptides, fusion proteins, and compositions thereof having improved binding affinity for the SARS-CoV-2 spike protein receptor binding domain relative to wild-type ACE2. Also provided are methods of using the recombinant ACE2 polypeptides, fusion proteins, and compositions thereof for treating subjects infected with a SARS-CoV-2 virus (i.e., subjects with COVID-19), subjects having symptoms suggestive of a SARS-CoV-2 infection, and subjects exposed to or at risk of exposure to SARS-CoV-2 virus. Other virus infections may also be treated.

Abstract: This disclosure describes techniques for performing application-based tagging. An example method includes receiving, at a virtual socket, non-packetized data from an application and generating, by the virtual socket, a label based on the application. One or more data packets are generated by packetizing at least a portion of the non-packetized data. A header field of the one or more data packets includes a tag based on the label.

Abstract: In various embodiments, a goods to operator workstation is provided. The goods to operator workstation include an upper level. The upper level includes an upper level conveyor and one or more upper level container bays configured to receive and present one of the one or more upper level containers. The goods to operator workstation also includes at least one connector panel extending from the upper level. The goods to operator workstation further includes a lower level coupled to the at least one connector panel. The lower level is configured to receive one or more lower level containers.